Mereo Biopharma Group Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 39

Employees

  • Stock Symbol
  • MREO

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $0.32
  • (As of Thursday Closing)

Mereo Biopharma Group General Information

Description

Developer of drugs and therapies catering to patients with rare diseases and cancer. The company is engaged in the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases.

Contact Information

Formerly Known As
Mereo Biopharma Group Limited
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 4th Floor, 1 Cavendish Place
  • London W1G 0QF
  • England, United Kingdom
+44 0333
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4th Floor, 1 Cavendish Place
  • London W1G 0QF
  • England, United Kingdom
+44 0333

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mereo Biopharma Group Stock Performance

As of 17-Dec-2020, Mereo Biopharma Group’s stock price is $0.32. Its current market cap is $121M with 339M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.32 $0.31 $0.17 - $0.66 $121M 339M 66.07 -$1.54

Mereo Biopharma Group Financials Summary

As of 30-Sep-2026, Mereo Biopharma Group has a trailing 12-month revenue of $800K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
Revenue 800 500 0 10,000
EBITDA (26,532) (42,647) (43,836) (28,187)
Net Income (26,938) (41,878) (43,253) (29,466)
Total Assets 29,583 45,917 76,390 66,499
Total Debt 577 202 6,429 5,952
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mereo Biopharma Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mereo Biopharma Group‘s full profile, request access.

Request a free trial

Mereo Biopharma Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs and therapies catering to patients with rare diseases and cancer. The company is engaged in the devel
Drug Discovery
London, United Kingdom
39 As of 2025

Cambridge, United Kingdom
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mereo Biopharma Group Competitors (14)

One of Mereo Biopharma Group’s 14 competitors is Biosceptre, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biosceptre Venture Capital-Backed Cambridge, United Kingdom
Genentech Formerly VC-backed South San Francisco, CA
Verona Pharma Corporate Backed or Acquired London, United Kingdom
Redx Pharma Venture Capital-Backed Macclesfield, United Kingdom
Sitryx Venture Capital-Backed Oxford, United Kingdom
You’re viewing 5 of 14 competitors. Get the full list »

Mereo Biopharma Group Patents

Mereo Biopharma Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023149978-A1 Cancer biomarkers and cancer treatments Inactive 04-Feb-2022
WO-2023149977-A1 Methods for treating cancer Inactive 04-Feb-2022
AU-2019380595-A1 Methods and monitoring of treatment with vegf/dll4 binding agent Inactive 15-Nov-2018
CA-3119458-A1 Methods and monitoring of treatment with vegf/dll4 binding agent Pending 15-Nov-2018
EP-3880697-A2 Methods and monitoring of treatment with vegf/dll4 binding agent Inactive 15-Nov-2018 C07K14/515
To view Mereo Biopharma Group’s complete patent history, request access »

Mereo Biopharma Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mereo Biopharma Group Investments & Acquisitions (2)

Mereo Biopharma Group’s most recent deal was a Merger/Acquisition with OncoMed Pharmaceuticals for . The deal was made on 23-Apr-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OncoMed Pharmaceuticals 23-Apr-2019 Merger/Acquisition Drug Discovery
Novartis (Mid-Stage Clinical Product Portfolio) 29-Jul-2015 Corporate Asset Purchase Buildings and Property
To view Mereo Biopharma Group’s complete investments and acquisitions history, request access »

Mereo Biopharma Group ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Mereo Biopharma Group’s complete esg history, request access »

Mereo Biopharma Group Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Mereo BioPharma Europe Amsterdam, Netherlands 2025
OncoMed Pharmaceuticals Redwood City, CA 2004

Mereo Biopharma Group FAQs

  • When was Mereo Biopharma Group founded?

    Mereo Biopharma Group was founded in 2015.

  • Where is Mereo Biopharma Group headquartered?

    Mereo Biopharma Group is headquartered in London, United Kingdom.

  • What is the size of Mereo Biopharma Group?

    Mereo Biopharma Group has 39 total employees.

  • What industry is Mereo Biopharma Group in?

    Mereo Biopharma Group’s primary industry is Drug Discovery.

  • Is Mereo Biopharma Group a private or public company?

    Mereo Biopharma Group is a Public company.

  • What is Mereo Biopharma Group’s stock symbol?

    The ticker symbol for Mereo Biopharma Group is MREO.

  • What is the current stock price of Mereo Biopharma Group?

    As of 17-Dec-2020 the stock price of Mereo Biopharma Group is $0.32.

  • What is the current market cap of Mereo Biopharma Group?

    The current market capitalization of Mereo Biopharma Group is $121M.

  • What is Mereo Biopharma Group’s current revenue?

    The trailing twelve month revenue for Mereo Biopharma Group is $800K.

  • Who are Mereo Biopharma Group’s competitors?

    Biosceptre, Genentech, Verona Pharma, Redx Pharma, and Sitryx are some of the 14 competitors of Mereo Biopharma Group.

  • What is Mereo Biopharma Group’s annual earnings per share (EPS)?

    Mereo Biopharma Group’s EPS for 12 months was -$1.54.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process